Search
Immunome Inc
IMNMAdd to Watchlist
18.740USD
+0.210+1.13%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
2.12BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Immunome Inc is 8.43, ranking 124 out of 389 in the Biotechnology & Medical Research industry. The average price target is 23.50, with a high of 38.00 and a low of 18.00.
Analyst Rating
Based on
14
analysts
Buy
Current Rating
35.500
Target Price
+89.43%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Immunome Inc
IMNM
14
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Immunome Inc's expected revenue for the next quarter?
Immunome Inc's expected revenue is 181.82K.
What is Immunome Inc's price target?
Analysts forecast that Immunome Inc's price target is USD 23.50, with the highest forecast at USD 38.00 and the lowest forecast at USD 18.00.
How have Immunome IncIMNM's recent earnings per share performed?
The market expectation was USD -0.48, while Immunome IncIMNM's earnings per share (EPS) for the previous quarter was USD -0.74. EPS for the next quarter is expected at USD -0.53.
What is the analyst rating for Immunome Inc?
Based on the ratings of Immunome Inc's stock from 14 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
